Drug Pipeline

Investigator's Choice Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
2
Phase 3
3
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-19 NCT06496178
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy…		 Primary endpoint(s) modified
2026-05-19 NCT06496178
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy…		 Enrollment increased: 500 -> 600 participants
2026-05-19 NCT06496178
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy…		 Trial sites expanded: 208 -> 214 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-10 NCT07639879 TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma Phase 3 Not Yet Recruiting
2026-05-20 NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
2
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06496178 A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy… Head and Neck Squamous Cell Carcinoma Recruiting
NCT07639879 TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma PTCL Not Yet Recruiting
Phase 2
NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… Large B-cell Lymphoma Not Yet Recruiting
Sponsors Running Investigator's Choice Trials
Merus B.V. (1) The First Affiliated Hospital of Soochow University (1) Tarapeutics Science Inc. (1)
Disease Areas
Head & Neck Cancer (1)
Get alerts when Investigator's Choice trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free